Guggenheim Maintains Buy on Avalo Therapeutics, Lowers Price Target to $48

Benzinga Newsdesk www.benzinga.com Neutral 72.5%

Neg 0% Neu 72.5% Pos 0%

Guggenheim analyst Yatin Suneja maintains Avalo Therapeutics (NASDAQ:AVTX) with a Buy and lowers the price target from $50 to $48.